Eterna Therapeutics (Eterna Therapeutics) 6-1 Month Momentum % : 91.53% (As of May. 12, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Eterna Therapeutics 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-05-12), Eterna Therapeutics's 6-1 Month Momentum % is 91.53%.

The industry rank for Eterna Therapeutics's 6-1 Month Momentum % or its related term are showing as below:

ERNA's 6-1 Month Momentum % is ranked better than
87.52% of 1531 companies
in the Biotechnology industry
Industry Median: 2.29 vs ERNA: 91.53

Competitive Comparison of Eterna Therapeutics's 6-1 Month Momentum %

For the Biotechnology subindustry, Eterna Therapeutics's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eterna Therapeutics's 6-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eterna Therapeutics's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Eterna Therapeutics's 6-1 Month Momentum % falls into.

Eterna Therapeutics (NAS:ERNA) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %

( Price 1-month ago

Price 6-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eterna Therapeutics (NAS:ERNA) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Eterna Therapeutics 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Eterna Therapeutics's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

Eterna Therapeutics (Eterna Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eterna Therapeutics Inc (NAS:ERNA) » Definitions » 6-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1035 Cambridge Street, Suite 18A, Cambridge, MA, USA, 02141

Website

https://www.eternatx.com

Eterna Therapeutics Inc is a biopharmaceutical company. The company develops transformational new medicines using various cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.

Executives

Dorothy J Clarke	director	C/O ETERNA THERAPEUTICS INC., 1035 CAMBRIDGE STREET, STE. 18A, CAMBRIDGE MA 02141
Charles Cherington	10 percent owner	ONE BOW STREET, CAMBRIDGE MA 02138
Brant Binder	director	C/O TRUST CO OF THE SWEST, 200 PARK AVE SUITE 220, NEW YORK NY 01066
Richard W Wagner	director	C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER ST, WALTHAM MA 02451
Curtis W Huft	10 percent owner	4510 LAMESA HWY, SNYDER TX 79549
Freebird Partners Lp	10 percent owner	2800 POST OAK BLVD., SUITE 2000, HOUSTON TX 77056
Freebird Investments Llc	10 percent owner	2800 POST OAK BLVD., SUITE 2000, HOUSTON TX 77056
John D Halpern	10 percent owner
Nicholas Jason Singer	director	1395 BRICKELL AVENUE, SUITE 800, MIAMI FL 33131
William A. Wexler	director	12 GILL STREET, SUITE 4650, WOBURN MA 01801
Gregory Fiore	director	10355 SCIENCE CENTER DRIVE, SUITE 150, SAN DIEGO CA 92121
Andrew C. Jackson	officer: Chief Financial Officer	11988 EL CAMINO REAL STE. 650, SAN DIEGO CA 92130
Matthew Angel	officer: Interim President and CEO	10531 4S COMMONS DRIVE, SUITE 160-550, SAN DIEGO CA 92127
Heather B Redman	director	TWO NORTH NINTH STREET, ALLENTOWN PA 18101
Erin S. Enright	director	666 PLAINSBORO ROAD, PLAINSBORO NJ 08536